TuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1% – Here’s Why

TuHURA Biosciences, Inc. (NASDAQ:HURA) dropped 3.1% on Friday . The stock traded as low as $1.87 and last traded at $1.90. Approximately 939,185 shares changed hands during trading, a decline of 17% from the average daily volume of 1,127,606 shares. The stock had previously closed at $1.96.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HURA. Wall Street Zen raised TuHURA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Maxim Group cut their price target on TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Stock Down 3.1%

The company has a market cap of $115.37 million, a P/E ratio of -3.80 and a beta of -0.30. The firm’s 50 day moving average is $1.06 and its two-hundred day moving average is $1.71.

Institutional Investors Weigh In On TuHURA Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in HURA. Vanguard Group Inc. raised its position in shares of TuHURA Biosciences by 1.6% during the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock worth $5,629,000 after acquiring an additional 35,426 shares during the last quarter. Geode Capital Management LLC boosted its holdings in TuHURA Biosciences by 6.4% in the fourth quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock valued at $501,000 after acquiring an additional 39,710 shares during the last quarter. State Street Corp boosted its holdings in TuHURA Biosciences by 4.9% in the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock valued at $219,000 after acquiring an additional 13,594 shares during the last quarter. Apollon Wealth Management LLC increased its position in TuHURA Biosciences by 15.8% during the 3rd quarter. Apollon Wealth Management LLC now owns 133,526 shares of the company’s stock valued at $331,000 after purchasing an additional 18,252 shares during the period. Finally, Deutsche Bank AG increased its position in TuHURA Biosciences by 209.8% during the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after purchasing an additional 54,051 shares during the period. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.